Child Safety Seat Registration,New Post from SaferAutomobiles.com

NHTSA is encouraging everyone to register their child restraint systems with the appropriate manufacturer. NHTSA’s website states:

In the event of a safety recall all manufacturers are required to notify all registered owners by first class mail that their child restraint is included in the recall. Therefore, it is very important that the manufacturer of your child restraint has your current mailing address, and all of the information necessary to identify your child restraint. To register your child restraint you will need to provide the following information:

• Your Name
• Your current mailing address
• Manufacturer’s Name (Example: Graco, Britax, Evenflo, Combi, etc.)
• Date of Manufacture (Example: Label says “Manufactured in” )
• Model Number (Example: 8643CDR2, 808688, 317147P1, etc.)
• Model Name (if known) (Example: Snugride, Centre EX, Embrace, etc.)

All manufacturers are required to include the model number and date of manufacture on each restraint they produce. It can be found on a label attached to the restraint (look on the rear, the bottom, or the side of the restraint). The images below are samples of what a label may look like. Please note that the label on your child restraint may look different from these sample labels.

Information regarding specific manufacturers and how to register can be found here.

Supreme Court rejects limits on drug lawsuits

Supreme Court rejects limits on drug lawsuits

By MARK SHERMAN

The Supreme Court on Wednesday upheld a $6.7 million jury award to a musician who lost her arm because of a botched injection of an anti-nausea medication. The court brushed away a plea that it limits lawsuits against drug makers.

In a 6-3 decision, the court rejected Wyeth Pharmaceuticals’ claim that federal approval of its Phenergan anti-nausea drug should have shielded the company from lawsuits like the one filed by Diana Levine of Vermont.

The decision is the second this term to reject business groups’ arguments that federal regulation effectively pre-empts consumer complaints under state law.

A Vermont jury agreed with Levine’s claim that Wyeth failed to provide a strong and clear warning about the risks of quickly injecting the drug into a vein. Gangrene is likely if the injection accidentally hits an artery – precisely what happened to Levine.

The company appealed and, backed by the Bush administration, argued that once a drug’s warning label gets approval from the Food and Drug Administration, the label can’t be changed without further FDA approval and consumers cannot pursue state law claims that they were harmed.

Justice John Paul Stevens, writing the majority opinion, said Wyeth could “unilaterally strengthen its warning.”